Bioage Labs Inc (BIOA) Stock Price, Quote & News

Company Profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease,...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 510 806 1445

Website: bioagelabs.com

Address:

5885 Hollis Street, Suite 370, EmeryVille, United States

MarketBeat Jun. 6 at 12:05 PM

https://marketbeat.com/a/8696909/ $BIOA BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

0 · Reply

xrpmoonbaby Jun. 5 at 2:07 AM

$BIOA I think everyone is sleeping on this. Will start to scale in heavy

0 · Reply

Congratulations May. 21 at 5:04 PM

limit buys. no market buys $LABT $BIOA $NRXP $ISPC $FDMT

0 · Reply

Congratulations May. 21 at 12:27 AM

$BIOA $LABT $NRXP $ISPC $FDMT 4/5 green works https://stocktwits.com/Congratulations/message/653952052

0 · Reply

Congratulations May. 20 at 6:33 PM

$BIOA $LABT $NRXP $ISPC $FDMT

0 · Reply

space4lyfe May. 16 at 11:11 PM

$BIOA I’ll put it here, this has 100x potential if you genuinely understand the drugs in the pipeline.

0 · Reply

MarketBeat May. 8 at 8:03 PM

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials $BIOA #BioAgeLabs #instantalerts #NASDAQ:BIOA

0 · Reply

focafoca99 May. 8 at 1:38 PM

$BIOA released its first-quarter 2026 financial results.

0 · Reply

bryyep649 May. 6 at 11:07 PM

$BIOA when I put bioage into grok it says it has a possible vaccine for hauntavirus. Maybe that’s why we saw the uptick today. Things that make you go hmmmmmm. Or it could be the Friday investor day

0 · Reply

ballerallday May. 6 at 7:22 PM

$BIOA Huge $475.9K call buying on the July 22.50s. 😲

0 · Reply

BioAge Labs Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 3:45 PM EDT - 6 days ago

BioAge Labs Transcript: Jefferies Global Healthcare Conference 2026

2026-05-27T08:20:08.000Z - 14 days ago

BioAge Labs initiated with a Buy at Roth Capital

May 22, 2026, 9:00 AM EDT - 19 days ago

BioAge Labs to Present at Upcoming Investor Conferences

2026-05-13T09:55:09.000Z - 4 weeks ago

BioAge Labs initiated with a Buy at BTIG

May 8, 2026, 12:30 PM EDT - 4 weeks ago

BioAge Labs Transcript: R&D Day 2026

May 8, 2026, 12:30 PM EDT - 4 weeks ago

BioAge Labs Slides: FY 2026

2026-05-08T15:21:29.000Z - 4 weeks ago

BioAge Labs reports Q1 EPS (52c), consensus (63c)

May 8, 2026, 9:00 AM EDT - 4 weeks ago

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

May 8, 2026, 7:00 AM EDT - 4 weeks ago

BioAge Labs Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 4 weeks ago

BioAge Labs Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 5 weeks ago

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

2026-04-21T12:30:33.000Z - 7 weeks ago

BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2

Apr 21, 2026, 8:00 AM EDT - 7 weeks ago

BioAge Labs Transcript: Study result

Apr 21, 2026, 8:00 AM EDT - 7 weeks ago

BioAge Labs Press release: Study result

Apr 21, 2026, 8:00 AM EDT - 7 weeks ago

BioAge Labs Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 7 weeks ago

BioAge Labs Proxy statement: Proxy filing

Apr 21, 2026, 7:00 AM EDT - 7 weeks ago

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

Apr 20, 2026, 7:00 AM EDT - 7 weeks ago

BioAge Labs Slides: Corporate presentation

Apr 16, 2026, 3:00 PM EDT - 7 weeks ago

BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 4:30 PM EDT - 2 months ago

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

2026-03-27T10:27:07.000Z - 2 months ago

BioAge Labs initiated with a Buy at Needham

2026-03-24T20:25:15.000Z - 2 months ago

BioAge Labs files automatic mixed securities shelf

Mar 24, 2026, 9:00 AM EDT - 2 months ago

BioAge Labs Annual report: Q4 2025

Mar 24, 2026, 9:00 AM EDT - 2 months ago

BioAge Labs Earnings release: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 2 months ago

BioAge Labs Slides: Corporate presentation

2026-03-10T10:41:09.000Z - 3 months ago

BioAge Labs price target raised to $52 from $15 at Citi

Feb 26, 2026, 10:40 AM EST - 3 months ago

BioAge Labs Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-24T21:48:29.000Z - 3 months ago

BioAge Labs initiated with an Outperform at Oppenheimer

VTYX

2026-02-18T11:10:46.000Z - 4 months ago

BioAge Labs upgraded to Buy from Hold at Jefferies

2026-02-04T13:36:59.000Z - 4 months ago

BioAge Labs price target raised to $23 from $12 at Morgan Stanley

2026-01-27T10:15:29.000Z - 4 months ago

BioAge Labs initiated with an Overweight at Piper Sandler

Jan 21, 2026, 10:30 PM EST - 4 months ago

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

2026-01-20T21:11:22.000Z - 5 months ago

BioAge Labs announces $75M common stock offering

Jan 20, 2026, 4:01 PM EST - 5 months ago

BioAge Announces Proposed Public Offering

2026-01-20T19:55:19.000Z - 5 months ago

BioAge Labs management to meet with Piper Sandler

2026-01-20T14:16:25.000Z - 5 months ago

BioAge Labs announces expansion of its BGE-102 development program

Jan 20, 2026, 9:00 AM EST - 5 months ago

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

Jan 20, 2026, 7:00 AM EST - 5 months ago

BioAge Labs Slides: Corporate presentation

2026-01-12T14:17:28.000Z - 5 months ago

BioAge Labs announces additional interim data from Phase 1 trial of BGE-102

Jan 12, 2026, 9:00 AM EST - 5 months ago

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

Dec 4, 2025, 1:30 PM EST - 6 months ago

BioAge Labs Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 9:00 AM EST - 6 months ago

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Nov 25, 2025, 4:30 PM EST - 7 months ago

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:30 AM EST - 7 months ago

BioAge Labs Transcript: Jefferies London Healthcare Conference 2025

Nov 7, 2025, 9:00 AM EST - 7 months ago

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

Nov 6, 2025, 4:00 PM EST - 7 months ago

BioAge Labs Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

BioAge Labs Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 7 months ago

BioAge Labs Registration statement: Registration Filing

Nov 5, 2025, 7:00 AM EST - 7 months ago

BioAge Labs Registration statement: Registration Filing

Oct 2, 2025, 8:00 AM EDT - 8 months ago

BioAge Labs Registration statement: Registration Filing

Oct 2, 2025, 8:00 AM EDT - 8 months ago

BioAge Labs Registration statement: Registration Filing

Sep 15, 2025, 9:30 AM EDT - 9 months ago

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

Sep 10, 2025, 10:00 AM EDT - 9 months ago

BioAge Labs Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 3:15 PM EDT - 10 months ago

BioAge Labs Transcript: Citi's Biopharma Back to School Conference

Aug 15, 2025, 9:00 AM EDT - 10 months ago

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Aug 6, 2025, 4:30 PM EDT - 11 months ago

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 4:00 PM EDT - 11 months ago

BioAge Labs Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

BioAge Labs Earnings release: Q2 2025

Jun 21, 2025, 6:00 PM EDT - 1 year ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Jun 17, 2025, 9:00 AM EDT - 1 year ago

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

Jun 9, 2025, 3:20 PM EDT - 1 year ago

BioAge Labs Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 6:00 AM EDT - 1 year ago

BioAge Labs Slides: Investor Presentation

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 12:00 AM EDT - 1 year ago

BioAge Labs Quarterly report: Q1 2025

May 6, 2025, 12:00 AM EDT - 1 year ago

BioAge Labs Earnings release: Q1 2025

Apr 17, 2025, 8:00 AM EDT - 1 year ago

BioAge Labs Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

BioAge Labs Proxy statement: Proxy Filing

Mar 20, 2025, 5:00 PM EDT - 1 year ago

BioAge Labs Annual report: Q4 2024

Mar 20, 2025, 5:00 PM EDT - 1 year ago

BioAge Labs Earnings release: Q4 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Mar 10, 2025, 9:30 PM EDT - 1 year ago

Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA

Mar 10, 2025, 6:33 PM EDT - 1 year ago

BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 5, 2025, 3:45 PM EST - 1 year ago

BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 2, 2025, 7:23 AM EST - 1 year ago

BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)

Feb 28, 2025, 3:30 PM EST - 1 year ago

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

MarketBeat Jun. 6 at 12:05 PM

https://marketbeat.com/a/8696909/ $BIOA BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

0 · Reply

xrpmoonbaby Jun. 5 at 2:07 AM

$BIOA I think everyone is sleeping on this. Will start to scale in heavy

0 · Reply

Congratulations May. 21 at 5:04 PM

limit buys. no market buys $LABT $BIOA $NRXP $ISPC $FDMT

0 · Reply

Congratulations May. 21 at 12:27 AM

$BIOA $LABT $NRXP $ISPC $FDMT 4/5 green works https://stocktwits.com/Congratulations/message/653952052

0 · Reply

Congratulations May. 20 at 6:33 PM

$BIOA $LABT $NRXP $ISPC $FDMT

0 · Reply

space4lyfe May. 16 at 11:11 PM

$BIOA I’ll put it here, this has 100x potential if you genuinely understand the drugs in the pipeline.

0 · Reply

MarketBeat May. 8 at 8:03 PM

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials $BIOA #BioAgeLabs #instantalerts #NASDAQ:BIOA

0 · Reply

focafoca99 May. 8 at 1:38 PM

$BIOA released its first-quarter 2026 financial results.

0 · Reply

bryyep649 May. 6 at 11:07 PM

0 · Reply

ballerallday May. 6 at 7:22 PM

$BIOA Huge $475.9K call buying on the July 22.50s. 😲

0 · Reply

CrocksAndPonds May. 4 at 5:52 PM

$BIOA Nice price on options here, just bought a batch at 16.36 and wrote May 15 $17.50 calls at .55

1 · Reply

romanaround Apr. 29 at 10:12 PM

$ALT $BIOA $TERN $VKTX gosh dang my apologies to tern and bioa they are on top kings

0 · Reply

skyrockets_Inc Apr. 21 at 5:08 PM

$VTGN Likely in coming weeks. They announced data as '1H 2026' instead of Q2. $BIOA announced the same thing '1H 2026' and just released their data today. I think we are due within weeks, possibly by end of April.

1 · Reply

Biotech_Pharma_Investor Apr. 21 at 2:44 PM

$BIOA Pros: - best-in-class reduction of inflammation - oral - brain-penetrant (allows ophthalmolgy and CNS indications) - huge TAMs - last funding at $19.5 - runway through 2029 - NVO and LLY partnerships Cons - too early stage (unless it gets acquired...) with many unknowns

0 · Reply

Biotech_Pharma_Investor Apr. 21 at 1:06 PM

$BIOA As clarified in the call headache was associated with lumbar punctures consucted in treatment arms for pk/pd studies

0 · Reply

Biotech_Pharma_Investor Apr. 21 at 12:20 PM

$BIOA Targeting/potential in many large TAMs: - CVD disease - obesity - DME, GA Room for >1 players too

0 · Reply

Biotech_Pharma_Investor Apr. 21 at 12:13 PM

$BIOA best hsCRP reduction + oral + brain-penetrant

0 · Reply

skyrockets_Inc Apr. 21 at 11:43 AM

$BIOA https://ir.bioagelabs.com/news-releases/news-release-details/bioage-reports-positive-phase-1-data-bge-102-novel-oral-nlrp3

0 · Reply

S2K_TP Apr. 18 at 5:41 PM

$BIOA still watching this 20 break at some point

0 · Reply

SuperGreenToday Mar. 27 at 6:43 PM

$BIOA Share Price: $16.27 Contract Selected: Dec 18, 2026 $22.5 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.36 – $1.67 Potential Upside: 52% ROI Time to Expiration: 265 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

notreload_ai Mar. 27 at 12:38 PM

Needham started coverage of $BIOA with a Buy rating and $50 price target. Analysts are bullish on lead asset BGE-102, an oral NLRP3 inhibitor for cardiovascular risk in obese patients. https://notreload.xyz/needham-initiates-buy-rating-on-bioage-labs/

0 · Reply

Market Cap	689.47M
Revenue (ttm)	9.00M
Net Income (ttm)	-80.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-895.67%
Debt to Equity Ratio	0.00

Volume	335,200
Avg Vol	408,950
Day's Range	N/A - N/A
Shares Out	44.45M
Stochastic %K	23%
Beta	0.94
Analysts	Strong Sell
Price Target	$49.50